Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029383 | 1.00 | EPHX1 (0.45) | EPHX1HDAC4POLBPKMPDK1 | |
| SCHEMBL3405244 | 1.00 | EPHX1 (0.45) | EPHX1HDAC4POLBPKMPDK1 | |
| Hydrochloric Acid SCHEMBL1873541 | 0.98 | EPHX1 (0.44) | EPHX1HDAC4POLBPKMPDK1 | |
| Hydrochloric Acid SCHEMBL1027224 | 0.98 | EPHX1 (0.44) | EPHX1HDAC4POLBPKMPDK1 | |
| Hydrochloric Acid SCHEMBL1878764 | 0.98 | EPHX1 (0.44) | EPHX1HDAC4POLBPKMPDK1 | |
| SCHEMBL5347904 | 0.89 | MAPK1 (0.43) | EPHX1HDAC4PKMPDK1PDK2 | |
| SCHEMBL5347905 | 0.89 | MAPK1 (0.43) | EPHX1HDAC4PKMPDK1PDK2 | |
| SCHEMBL5113323 | 0.89 | MAPK1 (0.43) | EPHX1HDAC4PKMPDK1PDK2 | |
| SCHEMBL4374405 | 0.88 | EPHX1 (0.59) | EPHX1HDAC4POLBPKMPDK1 | |
| Hydrochloric Acid SCHEMBL439397 | 0.86 | EPHX1 (0.57) | EPHX1HDAC4POLBPKMPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-2254893-A1 | NOVEL 7-SUBSTITUTED DERIVATIVES OF 3-CARBOXY-OXADIAZINO-QUINOLONES, PREPARATION THEREOF AND USE THEREOF AS ANTI-BACTERIAL AGENTS | VETOQUINOL S.A. (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009106967-A1 | NOVEL 7-SUBSTITUTED DERIVATIVES OF 3-CARBOXY-OXADIAZINO-QUINOLONES, PREPARATION THEREOF AND USE THEREOF AS ANTI-BACTERIAL AGENTS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | WO | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007062316-A2 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR ANTI-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7067509-B2 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040192926-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-09-30 | — | — | US | disclosed |
| WO-2004080411-A2 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2003053915-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003015778-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | EPHX1 2951/4885HDAC4 76/4885POLB 972/4885 |
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | EPHX1 1321/4885HDAC4 3175/4885POLB 4686/4885 |
| US-20070117986-A1 | TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS | HRH4, NR1I3, NR1I2 | EPHX1 2667/4885HDAC4 539/4885POLB 3968/4885 |
| US-20040192926-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | EPHX1 2048/4885HDAC4 2469/4885POLB 2548/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | EPHX1 3426/4885HDAC4 1611/4885POLB 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.